Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 7:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 59 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Treatment Resistant Depression (TRD) Clear all
Terminated Phase 2 Interventional Results available

Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression

NCT01913535
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
CERC-501, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Chicago, Illinois • Wichita, Kansas • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 23, 2026, 7:19 AM EDT
Completed Phase 1 Interventional

Multiple Ascending Dose Phase 1 Study of ALA-3000

NCT06965569
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
ALA-3000, Placebo, escitalopram, sertraline, duloxetine or venlafaxine XR
Drug
Lead sponsor
Alar Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
4
States / cities
Little Rock, Arkansas • St Louis, Missouri • Eatontown, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Jul 23, 2026, 7:19 AM EDT
Not yet recruiting Not applicable Interventional

Neuronavigated aiTBS for TRD

NCT07329153
View directory record Official record
Conditions
Treatment Resistant Depression (TRD)
Interventions
aiTBS
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
3
States / cities
San Diego, California • New York, New York • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Jul 23, 2026, 7:19 AM EDT
Completed Phase 3 Interventional

A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder

NCT02741791
View directory record Official record
Conditions
Treatment Resistant Major Depressive Disorder
Interventions
AXS-05, Bupropion
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
74
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 71 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Jul 23, 2026, 7:19 AM EDT
Completed Phase 4 Interventional Results available

A Study of Brexpiprazole Plus Ketamine in Treatment-Resistant Depression (TRD)

NCT03149991
View directory record Official record
Conditions
Depression
Interventions
Brexpiprazole, Ketamine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
6
States / cities
Garden Grove, California • Oakland, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Jul 23, 2026, 7:19 AM EDT
Active, not recruiting Phase 2 Interventional

An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)

NCT04433858
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Psilocybin
Drug
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Palo Alto, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Jul 23, 2026, 7:19 AM EDT
Active, not recruiting Not applicable Interventional

DBS of the Lateral Habenula in Treatment-Resistant Depression

NCT01798407
View directory record Official record
Conditions
Treatment Resistant Major Depressive Disorder
Interventions
Activa Tremor Control Sys (DBS Implant), Randomized, staggered withdrawal phase
Device · Other
Lead sponsor
Wayne Goodman MD
Other
Eligibility
21 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 27, 2025 · Synced Jul 23, 2026, 7:19 AM EDT
Completed No phase listed Observational Results available

Treatment-Resistant Depression Registry

NCT00320372
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Not listed
Lead sponsor
Cyberonics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
795 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
55
States / cities
Tucson, Arizona • Beverly Hills, California • Garden Grove, California + 46 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2015 · Synced Jul 23, 2026, 7:19 AM EDT
Active, not recruiting Phase 3 Interventional

Psilocybin-Assisted Therapy in Treatment-Resistant Depression

NCT06303739
View directory record Official record
Conditions
Refractory Depression, Treatment Resistant Depression
Interventions
psilocybin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 23, 2026, 7:19 AM EDT
Not yet recruiting Phase 3 Interventional

Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression

NCT07226232
View directory record Official record
Conditions
Major Depression
Interventions
Psilocybin
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
5
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 23, 2026, 7:19 AM EDT
Completed Not applicable Interventional Results available

Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression (SAINT-TRD)

NCT03068715
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Active TBS-DLPFC, Sham TBS-DLPFC, Open label TBS-DLPFC
Device
Lead sponsor
Stanford University
Other
Eligibility
22 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Jul 23, 2026, 7:19 AM EDT
Completed Phase 2 Interventional Results available

A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD

NCT05414422
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
PCN-101, Placebo
Drug
Lead sponsor
Perception Neuroscience
Industry
Eligibility
18 Years to 65 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
13
States / cities
Little Rock, Arkansas • Garden Grove, California • La Jolla, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Jul 23, 2026, 7:19 AM EDT
Recruiting Not applicable Interventional

taVNS or TMS or Both for Depression

NCT05725239
View directory record Official record
Conditions
Depression
Interventions
Vagus Nerve Stimulation, Transcranial Magnetic Stimulation
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 23, 2026, 7:19 AM EDT
Completed Not applicable Interventional Results available

Deep Brain Stimulation (DBS) for Treatment-Resistant Depression (TRD)

NCT01898429
View directory record Official record
Conditions
Treatment Resistant Depression, Depressive Disorder, Treatment-Resistant, Depression, Bipolar
Interventions
SCC DBS
Device
Lead sponsor
Paul Holtzheimer
Other
Eligibility
22 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Jul 23, 2026, 7:19 AM EDT
Active, not recruiting Not applicable Interventional

Transcranial Electric Stimulation Therapy (TEST) for Treatment Resistant Depression (TRD)

NCT05172271
View directory record Official record
Conditions
Major Depressive Disorder, Bipolar Disorder, Unipolar Major Depression
Interventions
MagPro TMS Stimulator and coil, Thymatron(R) System IV, Magnetic Resonance Imaging Scanner, ECT device without stimulation
Device · Other
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
25 Years to 64 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 23, 2026, 7:19 AM EDT
Active, not recruiting Phase 3 Interventional

Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

NCT05711940
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Psilocybin
Drug
Lead sponsor
COMPASS Pathways
Industry
Eligibility
18 Years and older
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
62
States / cities
Gilbert, Arizona • Bellflower, California • Encino, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Jul 23, 2026, 7:19 AM EDT
Completed Not applicable Interventional Results available

Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)

NCT02452892
View directory record Official record
Conditions
Depression, Depressive Disorder, Depressive Disorder, Treatment-resistant, Depressive Disorder, Major
Interventions
LFMS
Device
Lead sponsor
Tal Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
12
States / cities
Garden Grove, California • Lemon Grove, California • Oakland, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Jul 23, 2026, 7:19 AM EDT
Completed Phase 2 Interventional

Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression

NCT01246908
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Placebo, CX157 (TriRima)
Drug
Lead sponsor
CeNeRx BioPharma Inc.
Industry
Eligibility
20 Years to 65 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
30
States / cities
Escondido, California • National City, California • Oceanside, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2012 · Synced Jul 23, 2026, 7:19 AM EDT
Recruiting Phase 2 Interventional

ALTO-207 in Adults With Treatment-resistant Depression (TRD)

NCT07553637
View directory record Official record
Conditions
Treatment-resistant Depression (TRD)
Interventions
ALTO-207, Placebo
Drug
Lead sponsor
Alto Neuroscience
Industry
Eligibility
18 Years to 75 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
38
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Jul 23, 2026, 7:19 AM EDT
Recruiting Phase 2 Interventional

Intravenous Ketamine for Treatment-Resistant Depression

NCT06668571
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant, Treatment Resistant Depression (TRD)
Interventions
Ketamine, Normal Saline
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Jul 23, 2026, 7:19 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Investigational TMS Treatment for Depression

NCT03175887
View directory record Official record
Conditions
Depression, Treatment Resistant Depression
Interventions
TMS
Device
Lead sponsor
White River Junction Veterans Affairs Medical Center
Federal
Eligibility
21 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
White River Junction, Vermont
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Jul 23, 2026, 7:19 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Aripiprazole as Augmentation for TRD

NCT00174876
View directory record Official record
Conditions
Depression
Interventions
Drug Abilify
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2008 · Synced Jul 23, 2026, 7:19 AM EDT
Active, not recruiting Phase 3 Interventional

Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD

NCT05624268
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Psilocybin
Drug
Lead sponsor
COMPASS Pathways
Industry
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
40
States / cities
Tucson, Arizona • Culver City, California • Garden Grove, California + 30 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Jul 23, 2026, 7:19 AM EDT
Completed Phase 2 Interventional Results available

Optimization of IV Ketamine for Treatment Resistant Depression

NCT00768430
View directory record Official record
Conditions
Major Depressive Disorder (MDD), Treatment Resistant Depression (TRD)
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
21 Years to 80 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2014 · Synced Jul 23, 2026, 7:19 AM EDT